BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Receives $16.71 Average Target Price from Analysts
Shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Free Report) have been given an average recommendation of “Hold” by the seven brokerages that are presently covering the firm, MarketBeat Ratings reports. Four analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month […]
More Stories
Gold Prices Surge to Highest Level in Over 3 Months
By Naveen Athrappully Gold prices are trading at their highest level in more than three months on Monday, amid continued...
Treasury, IRS Propose Rules on Trump Account Investments
By Naveen Athrappully The Department of the Treasury and the IRS have issued proposed regulations clarifying which investments may be...
Iryna Zarutska’s Family Sues City of Charlotte Over Fatal Rail Stabbing, Blaming Security Failures
By Owen Evans The family of 23-year-old Ukrainian refugee Iryna Zarutska, who was stabbed to death in North Carolina, has...
IndyCar Race Caps Summer Events for America’s 250th Birthday
By Travis Gillmore WASHINGTON—More than 100,000 spectators lined the streets to witness history as drivers raced by national monuments on...
Zelenskyy Rejects Calls for Wartime Elections in Ukraine
By Tom Gantert Ukrainian President Volodymyr Zelenskyy said holding elections during the war with Russia would “destroy the country,” in...
DOJ Says Diplomat Discipline Board Can’t Overrule Secretary of State
By Matthew Vadum A Department of Justice (DOJ) body held that an independent board that reviews disciplinary actions against U.S....